Humana entered into an underwriting agreement with the underwriters on March 11, 2024 to issue and sell $1,250 million of 5.375% Senior Notes due 2031 and $1,000 million of 5.750% Senior Notes due 2054.

1. 01

   Humana entered into an underwriting agreement with the underwriters on March 11, 2024 to issue and sell $1,250 million of 5.375% Senior Notes due 2031 and $1,000 million of 5.750% Senior Notes due 2054.

2. 02

   The company sold the 2031 Senior Notes at 99.940% of principal amount and the 2054 Senior Notes at 99.949% of principal amount. It estimated net proceeds after underwriting discounts, commissions and offering expenses at about $2.226 billion.

3. 03

   The company said it plans to use the net proceeds from the Senior Notes for general corporate purposes, which may include repaying existing debt, including borrowings under its commercial paper program.

4. 04

   The company completed the public offering on March 13, 2024. The notes are unsecured senior obligations, with interest payable semiannually on April 15 and October 15. The 2031 Senior Notes mature on April 15, 2031, and the 2054 Senior Notes mature on April 15, 2054.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.